US site closures as Takeda restructures vaccines business
This article was originally published in Scrip
Executive Summary
A fundamental restructuring of Takeda Pharmaceutical's vaccines operations will see the closure of three sites in the US as it consolidates operations in this market in the Boston area as part of a revised global network for the unit.
You may also be interested in...
Asia Deal Watch: Emmaus, Kainos Pursue R&D In Cancers With Limited Therapy Options
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Chordia Looks To Forge Own Path In Oncology
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
Quick Listen: Scrip’s Five Must-Know Things
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: